Gastrointestinal (GI) cancers have the highest incidence and are the second leading cause of cancer deaths in the United States (after lung cancer). At Alfa Cytology, our team of seasoned biological experts has dedicated themselves to unraveling the intricate mechanisms underlying gastrointestinal cancer development and progression.
Introduction to Gastrointestinal Cancer
Gastrointestinal (GI) cancers, encompassing a diverse range of malignancies affecting the digestive system, pose a significant global health challenge. These complex and often aggressive diseases, which include cancers of the esophagus, stomach, small intestine, colon, rectum, and liver, account for a substantial proportion of cancer-related morbidity and mortality worldwide. The heterogeneity of GI cancers, marked by their varied etiologies, and molecular profiles, has long hindered the development of comprehensive treatment strategies.
| Cancer site |
Estimated new cases |
Estimated deaths |
| Both sexes |
Male |
Female |
Both sexes |
Male |
Female |
| Digestive system |
353,820 |
197,390 |
156,430 |
174,320 |
100,310 |
74,010 |
| Esophagus |
22,370 |
17,690 |
4,680 |
16,130 |
12,880 |
3,250 |
| Stomach |
26,890 |
16,160 |
10,730 |
10,880 |
6,490 |
4,390 |
| Small intestine |
12,440 |
6730 |
5,710 |
2,090 |
1,150 |
940 |
| Colon & rectum |
152,810 |
81,540 |
71,270 |
53,010 |
28,700 |
24,310 |
| Colon |
106,590 |
54,210 |
52,380 |
|
|
|
| Rectum |
46,220 |
27,330 |
18,890 |
|
|
|
| Anus, anal canal, & anorectum |
10,540 |
3360 |
7,180 |
2,190 |
1,000 |
1,190 |
| Liver & intrahepatic bile duct |
41,630 |
28,000 |
13,630 |
29,840 |
19,120 |
10,720 |
| Gallbladder & other biliary |
12,350 |
5,900 |
6,450 |
4,530 |
1,950 |
2,580 |
| Pancreas |
66,440 |
34,530 |
31,910 |
51,750 |
27,270 |
24,480 |
| Other digestive organs |
8,350 |
3,480 |
4,870 |
3,900 |
1,750 |
2,150 |
The gastrointestinal cancer treatment market is poised for substantial growth, driven by the rising incidence of GI cancers, the unmet clinical needs, and the relentless pursuit of more effective and personalized therapeutic solutions. According to industry analysts, the global GI cancer treatment market is projected to reach over $70 billion by 2028, expanding at a robust CAGR of 8.2% during the forecast period. The complex and multifaceted nature of GI cancers, coupled with the limitations of existing treatment modalities, has fueled the demand for innovative approaches that can overcome drug resistance and enhance quality of life.
Our Services
This surge in market size underscores the increasing demand for effective and innovative therapy solutions for gastrointestinal cancer. Committed to staying at the forefront of the rapidly evolving field of gastrointestinal cancer research, Alfa Cytology continuously invests in the development of innovative technologies and the expansion of its service offerings.
Alfa Cytology is committed to the research and study of cancer, from cell therapy development services, immune checkpoint inhibitor development services, to cancer drug development services, providing one-stop solutions. Our preclinical services encompass a wide range of capabilities, including cell line development, high-throughput screening,
pharmacokinetic and pharmacodynamic evaluations, and advanced animal models. For more information about our gastrointestinal cancer research services and how we can support your drug development initiatives, please don't hesitate to contact us.
For research use only.
Related Services
